IPC launches 10 new impurities standards

With this, IPC will have a total of 410 impurity standards in its database, which is available for sale at www.ipc.gov.in

The Health Master

December 29, 2022

583

Table of Contents

Last Updated on October 10, 2024 by The Health Master

The Indian Pharmacopoeia Commission (IPC) has launched 10 new impurity standards for effective quality control analysis of pharmaceutical products in the country.

With this, IPC will have a total of 410 impurity standards in its database, which is available for sale at www.ipc.gov.in for drug manufacturing companies and testing labs in the country.

“We are planning to increase the number of impurity standards in our IPC product catalog and have set the target of having 500 impurity standards by March 2023.”

“Previously, manufacturers and other stakeholders sourced these standards from the British Pharmacopoeia or the US Pharmacopoeia (USP), but now IPC is making them available at standardized rates under one platform,” says Dr. Rajiv Singh Raghuvanshi, secretary-cum-scientific director of IPC.

Click for more articles on IPC

10 Impurity standards

The names of the impurity standards are:

Dolutegravir-4-fluoro impurity,
Ethyl paraben,
Fumaric acid (Lamivudine and Tenofovir tablets),
Ketorolac-1-hydoxy analog,
Mesalazine impurity F,

Fumaric acid (Maleic Acid),
Methotrexate impurity A,
Risperidone trans -N-oxide,
Terbinafine related compound B
Fumaric acid (Quetiapine Fumarate).

Click here to purchase impurity standards online

IPC in the month of July had launched the ninth edition of the Indian Pharmacopoeia (IP).

IP is recognized as the official book of standards for the drugs being manufactured and/or marketed in India.

IP contains a collection of authoritative procedures of analysis and specifications of drugs for their identity, purity and strength.

The standards of the IP are authoritative in nature and are enforced by the regulatory authorities for ensuring the quality of drugs in India.

During quality assurance and at the time of a dispute in court, the IP standards are legally acceptable.

The standards prescribed in the IP are to establish the article’s compliance with regulatory requirements.

The determination of unwanted compounds in pharmaceuticals is critical to addressing the safety, quality, and purity of drug substances and finished products.

Types of impurities

International Council for Harmonization (ICH) Q3A – Q3E guidance outlines five primary categories for impurities associated with pharmaceuticals, which consist of:

Impurities in new drug substances,
Impurities in new drug products,
Residual solvents,
Elemental impurities,
Extractables and leachables (E&L).

Effect of impurities

Impurities can affect the safety and efficacy of pharmaceuticals and biologic drugs, resulting in the potential recall of marketed drugs or the extension of drug development timelines, as these unwanted chemicals remain with the drug formulation or active pharmaceutical ingredient (API).

Impurities can be introduced from a variety of sources, from API and/or excipient degradation, to manufacturing processes, including process impurities, process aids, and residual solvents, or from container-closure contact and storage.

Drug impurities are unwanted chemicals that remain with the active pharmaceutical ingredients, develop during formulation, or occur during the aging process of both the active pharmaceutical ingredients and the formulation, and are subject to analysis and rigorous testing for quality assurance.